MENU
ENTO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Entero Therapeutics (ENTO) Ownership - Who owns Entero Therapeutics?
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
3M
P/E Ratio
0.05
Total Cash
11.37M
Projected Growth
N/A
Total Debt
6.98M
Revenue
N/A
Risk (Beta)
0.98
Dividend Yield
N/A
Total Cash/Share
2.39
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ENTO
Capitalization
3M
P/E Ratio
0.05
Risk (Beta)
0.98
Dividend Yield
N/A
Total Cash
11.4M
Total Cash/Share
2.39
Total Debt
6.98M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
16.2M
P/B Ratio
0.33
Cash Flow
N/A
Earnings
-8.3
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
203
Current Ratio
1.21
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-20.9M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-13.33
Shares Held By Institutions
192K
Shares Outstanding - Current
4.75M
Total Liabilities
13.3M
Total Volume MTD
N/A
Value
1
Gain YTD
-85.000
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information